Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Intellia Therapeutics (NTLA – Research Report). The associated price target is $74.00.
Whitney Ijem has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising future prospects. The company’s 4Q24 earnings report was straightforward, with significant progress in its key programs. Notably, Intellia is on track with its TTR program, aiming to enroll at least 550 patients by the end of the year, despite facing competition in the field.
Additionally, the company has made advancements in its HAE program, successfully dosing its first patient in the Phase 3 HAELO trial and targeting completion of patient enrollment in the second half of 2025. Financially, Intellia is in a strong position, ending 4Q24 with $861.7 million in cash, which is expected to fund operations into the first half of 2027. Furthermore, the company has provided guidance on future operating expenses, anticipating a 5-10% year-over-year decline in 2025, followed by stabilization through 2027 as clinical trial costs decrease. These factors collectively support the Buy rating with a price target of $74.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $26.00 price target.
NTLA’s price has also changed dramatically for the past six months – from $22.940 to $10.860, which is a -52.66% drop .